“Panacea Biotech restructured the company around Covid. They have paid off all their debt. It is a debt-free company. They got out of low production markets like India and Nepal, which is where they did their portfolio immunization. And now they are focusing more on developed nations.”
Subscribe To Our Free Newsletter |